General Announcement::Glenmark Specialty S.A. receives approval for conducting Clinical Trial of its Novel Molecule

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
11-Apr-2022 13:05:12
Status
New
Announcement Sub Title
Glenmark Specialty S.A. receives approval for conducting Clinical Trial of its Novel Molecule
Announcement Reference
SG220411OTHRU6L1
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
11/04/2022 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin s Lymphoma.

Attachments

SGX_Press Release_11042022.pdf
Total size =915K